[A21-82] Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2021
Project no.:
A21-82
Commission:
Commission awarded on 15.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-39 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-82 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-81 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-14 | Venetoclax (chronic lymphocytic leukaemia) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| A21-138 | Venetoclax (acute myeloid leukaemia) - Addendum to commission A21-82 | Commission completed |
Federal Joint Committee (G-BA)
2021-12-02 A G-BA decision was published.